Q1. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:
· CAPOX (Capecitabine with Oxaliplatin) 13
· FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) 0
· Lonsurf (Trifluridine - tipiracil) <5
· Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) 0
· Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) 9
· Any other systemic anti-cancer therapy <5
· Palliative care only Data is not available from IQemo
Q2. How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with:
· Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine) 0
· Nivolumab monotherapy 5
· Nivolumab and Ipilimumab 0
· Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) 9
· Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) 18
· Any other systemic anti-cancer therapy <5
· Palliative care only Data is not available from IQemo
Q3. How many patients were treated in the past 3 months for advanced/metastatic oesophageal cancer ONLY with:
· Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine) 0
· Nivolumab monotherapy 5
· Nivolumab and Ipilimumab 0
· Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) 0
· Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) 9
· Any other systemic anti-cancer therapy <5
· Palliative care only Data is not available from IQemo
Q4. Does your trust participate in any clinical trials for gastric cancer? If so, please provide the name of each trial and the number of patients taking part.
We have a study open and recruiting called DETECT-ASCEND2. This study recruits patients for both gastric and oesophageal. We have 16 participants taking part.
Q5. Does your trust participate in any clinical trials for oesophageal cancer? If so, please provide the name of each trial and the number of patients taking part.
We have a study open and recruiting called DETECT-ASCEND2. This study recruits patients for both gastric and oesophageal. We have 16 participants taking part.
IQemo doesn't differentiate well between Gastric cancer, advanced / metastatic Oesophageal cancer or Gastro-oesophageal junction. We can give a breakdown of all patients who have all these diagnoses but can’t narrow down specifically.
